Pharma Pulse: Novartis Acquires Avidity and Trump's Tariff Threat
This episode of Pharma Pulse discusses Novartis' $12 billion acquisition of Avidity Biosciences and President Trump's proposed 10% tariff increase on Canadian imports.
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast covering patient access, supply chain/logistics, data & tech, and healthcare innovation.
Novartis' Acquisition and Trade Tensions
Novartis' $12 billion acquisition of Avidity Biosciences expands its RNA therapeutics portfolio. Meanwhile, President Trump's proposed tariff hike on Canadian imports could disrupt pharma supply chains.
From billion-dollar biotech deals to potential tariff shocks, these developments illustrate the critical interplay between science, business, and policy shaping pharma's global landscape.
For more insights, visit pharmaceuticalcommerce.com.
Author's summary: Novartis buys Avidity for $12B amidst trade tensions.
More News
- SKIMS’ chilling vision of the perfect female body
- You can’t rebrand genocide - The Poly Post
- Goodbye to life—Scientists confirm that Earth's oxygen will disappear much sooner than we thought
- Brookfield/Cameco-owned Westinghouse secures US nuclear construction deal
- ‘AI drives modern innovations’ - Star of Mysore
- The Best U.S. Cities for Ghosts to Live, Mapped
- Navigating shifting module costs and falling power prices at PV ModuleTech Europe 2025
- MLB: The Last 10 World Series MVPs
- Importing beef is not the solution | GABEL
- In Review: Big-Ass Sword by Andreas Butzbach